



M Colleoni

Contact

M Colleoni

Publications (25)

Luen S, Regan M, Colleoni M, Di Leo A, Viale G, Thürlimann B, Hackl W, Demanse D, Biasi O, Dell'orto P, Kammler R, Savas P, Lee C, Asher R, Loi S. Identifying oncogenic drivers associated with increased risk of late distant recurrence in postmenopausal, estrogen receptor-positive, HER2-negative early breast cancer: results from the BIG 1-98 study. *Ann Oncol* 2020; 31:1359-1365.

Burstein H, Thürlimann B, Winer E, Senn H, Regan M, Piccart-Gebhart M, Denkert C, Colleoni M, Poortmans P, Gnant M, Dubsy P, Loibl S, Curigliano G, Members of the St. Gallen International Consensus Panel on the Primary Therapy of Early Breast Cancer 2019. Estimating the benefits of therapy for early-stage breast cancer: the St. Gallen International Consensus Guidelines for the primary therapy of early breast cancer 2019. *Ann Oncol* 2019; 30:1541-1557.

Curigliano G, Thürlimann B, Senn H, Piccart-Gebhart M, Regan M, Colleoni M, Loibl S, Dubsy P, Gnant M, P Winer E, Burstein H, Panel Members of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2017. Corrections to "De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017". *Ann Oncol* 2019; 30:1181.

Burstein H, Thürlimann B, Winer E, Senn H, Regan M, Piccart-Gebhart M, Denkert C, Colleoni M, Poortmans P, Gnant M, Dubsy P, Loibl S, Curigliano G, Members of the St. Gallen International Consensus Panel on the Primary Therapy of Early Breast Cancer 2019. Estimating the benefits of therapy for early-stage breast cancer: the St. Gallen International Consensus Guidelines for the primary therapy of early breast cancer 2019. *Ann Oncol* 2019; 30:1541-1557.

Curigliano G, Thürlimann B, Senn H, Piccart-Gebhart M, Regan M, Colleoni M, Loibl S, Dubsy P, Gnant M, P Winer E, Burstein H, Panel Members of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2017. De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017. *Ann Oncol* 2019; 30:1181.

Xu B, Osborne K, Orecchia R, Morrow M, Karlsson P, Jiang Z, Jassem J, Khaled H, Huober J, Huang C, Hayes D, Harbeck N, Pagani O, Partridge A, Pritchard K, Whelan T, Watanabe T, Viale G, Tutt A, Toi M, Smith I, Shao Z, Semiglazov V, Sedlmayer F, Rutgers E, Ro J, Goodwin P, Gulluoglu B, André F, Thürlimann B, Senn H, Piccart-Gebhart M, Regan M, Colleoni M, Loibl S, Dubsy P, Gnant M, Winer E, Burstein H, Baselga J, Bergh J, Bonnefoi H, Garber J, Galimberti V, Francis P, Ejlersen B, Di Leo A, Denkert C, Cuzick J, Ciruelos E, Carey L, Cardoso F, Brucker S, Curigliano G. De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017. *Ann Oncol* 2018; 29:2153.

Gennari A, Bernhard J, Morales S, Pagani O, Barbeaux A, Borstnar S, Rabaglio-Poretti M, Maibach R, Regan M, Ribi K, Amillano Parraga K, Walshe J, Sun Z, Hasler-Strub U, Colleoni M, Kennedy M, von Moos R, Cortes J, Vidal M, Hennessy B, Jerusalem G. A randomized phase II study evaluating different maintenance schedules of nab-Paclitaxel in the first-line treatment of metastatic breast cancer: final results of the IBCSG 42-12/BIG 2-12 SNAP trial. *Ann Oncol* 2017

Di Cosimo S, Ng W, Colleoni M, Ferro A, Naume B, Patel A, Huober J, Piccart-Gebhart M, Baselga J, Vinholes J, Fein L, Fumagalli D, Campbell C, Azim H, Galli G, Bregni G, Curigliano G, Criscitiello C, Izquierdo M, de la Pena L, De Azambuja E. The use of breast imaging for predicting response to neoadjuvant lapatinib, trastuzumab and their combination in HER2-positive breast cancer: Results from Neo-ALTTO. *Eur J Cancer* 2017; 89:42-48.

Xu B, Osborne K, Orecchia R, Morrow M, Karlsson P, Jiang Z, Jassem J, Khaled H, Huober J, Huang C, Hayes D, Harbeck N, Pagani O, Partridge A, Pritchard K, Whelan T, Watanabe T, Viale G, Tutt A, Toi M, Smith I, Shao Z, Semiglazov V, Sedlmayer F, Rutgers E, Ro J, Goodwin P, Gulluoglu B, Garber J, Thürlimann B, Senn H, Piccart-Gebhart M, Regan M, Colleoni M, Loibl S, Dubsy P, Gnant M, Winer E, Burstein H, André F, Baselga J, Bergh J, Galimberti V, Francis P, Ejlertsen B, Di Leo A, Denkert C, Cuzick J, Ciruelos E, Carey L, Cardoso F, Brucker S, Bonnefoi H, Curigliano G. Reply to "The St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2017: the point of view of an International Panel of Experts in Radiation Oncology" by Kirova et al. *Ann Oncol* 2017

Regan M, Goldhirsch A, Coates A, Gelber R, Abdi E, Ruhstaller T, Parmar V, Spazzapan S, Salim M, Pinotti G, Tondini C, Colleoni M, Gómez H, Láng I, Fleming G, Francis P, Walley B, Pagani O. Concurrent and sequential initiation of ovarian function suppression with chemotherapy in premenopausal women with endocrine-responsive early breast cancer: an exploratory analysis of TEXT and SOFT. *Ann Oncol* 2017; 28:2225-2232.

Xu B, Osborne K, Orecchia R, Morrow M, Karlsson P, Jiang Z, Jassem J, Hussein K, Huober J, Huang C, Hayes D, Harbeck N, Pagani O, Partridge A, Pritchard K, Whelan T, Watanabe T, Viale G, Tutt A, Toi M, Smith I, Shao Z, Semiglazov V, Sedlmayer F, Rutgers E, Ro J, Goodwin P, Gulluoglu B, Garber J, Thürlimann B, Senn H, Piccart-Gebhart M, Regan M, Colleoni M, Loibl S, Dubsy P, Gnant M, P Winer E, Burstein H, André F, Baselga J, Bergh J, Galimberti V, Francis P, Ejlertsen B, Di Leo A, Denkert C, Cuzick J, Ciruelos E, Carey L, Cardoso F, Y Brucker S, Bonnefoi H, Curigliano G. De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017. *Ann Oncol* 2017; 28:1700-1712.

Munzone E, Colleoni M, Goldhirsch A, Coates A, Gelber R, Price K, Lelkaitis G, Bibeau F, Macgrogan G, Ejlertsen B, Thürlimann B, Viale G, Mallon E, Gusterson B, Giobbie-Hurder A, International Breast Cancer Study Group and the BIG 1-98 Collaborative Group. Outcomes of special histotypes of breast cancer after adjuvant endocrine therapy with letrozole or tamoxifen in the monotherapy cohort of the BIG 1-98 trial. *Ann Oncol* 2015

Huober J, Thürlimann B, Gelber R, Colleoni M, Coates A, Goldhirsch A, Price K, Wardley A, Smith I, Láng I, Neven P, Forbes J, Bonnefoi H, Ejlertsen B, Wu J, Giobbie-Hurder A, Rabaglio M, Cole B, BIG 1-98 Collaborative and International Breast Cancer Study Groups. Symptoms of endocrine treatment and outcome in the BIG 1-98 study. *Breast Cancer Res Treat* 2013; 143:159-69.

Viale G, Thürlimann B, Mouridsen H, Mauriac L, Gelber R, Price K, Goldhirsch A, Gusterson B, Coates A, Láng I, Colleoni M, Regan M, Dell'orto P, Mastropasqua M, Maiorano E, Rasmussen B, Macgrogan G, Forbes J, Paridaens R, for the BIG 1-98 Collaborative and International Breast Cancer Study Groups. Which patients benefit most from adjuvant aromatase inhibitors? Results using a composite measure of prognostic risk in the BIG 1-98 randomized trial. *Ann Oncol* 2011; 22:2201-2207.

Rabaglio M, Coates A, Goldhirsch A, Gelber R, Smith I, Láng I, Nogaret J, Pienkowski T, Colleoni M, Paridaens R, Forbes J, Campone M, Mouridsen H, Thürlimann B, Hawle H, Castiglione-Gertsch M, Price K, Sun Z, BIG 1-98 Collaborative and International Breast Cancer Study Groups. Bone fractures among postmenopausal patients with endocrine-responsive early breast cancer treated with 5 years of letrozole or tamoxifen in the BIG 1-98 trial. *Ann Oncol* 2009; 20:1489-98.

Colleoni M, Goldhirsch A, Price K, Viale G, Aebi S, Cinieri S, Peccatori F, Green M, Gelber R, Coates A, Basser R, Martinelli G, Sun Z, International Breast Cancer Study Group. The effect of endocrine responsiveness on high-risk breast cancer treated with dose-intensive chemotherapy: results of International Breast Cancer Study Group Trial 15-95 after prolonged follow-up. *Ann Oncol* 2009; 20:1344-51.

Viale G, Goldhirsch A, Gelber R, Öhlschlegel C, Karlsson P, Crivellari D, Golouh R, Brown R, Price K, Regan M, Castiglione-Gertsch M, Colleoni M, Mallon E, Sonzogni A, Mastropasqua M, Maiorano E, Gusterson B, Giobbie-Hurder A, Coates A. Adverse prognostic value of peritumoral vascular invasion: is it abrogated by adequate endocrine adjuvant therapy? Results from two International Breast Cancer Study Group randomized trials of chemoendocrine adjuvant therapy for early breast cancer. *Ann Oncol* 2009; 21:245-54.

Bernhard J, Coates A, Goldhirsch A, Price K, Castiglione-Gertsch M, Gelber R, Colleoni M, Green M, Thürlimann B, Yeo W, Aebi S, Forbes J, Hürny C, Basser R, Martinelli G, Zhang J, Zahrieh D, International Breast Cancer Study Group. Quality of life and quality-adjusted survival (Q-TWiST) in patients receiving dose-intensive or standard dose chemotherapy for high-risk primary breast cancer. *BJC* 2008; 98:25-33.

Keshaviah A, Coates A, Gelber R, Castiglione Gertsch M, Simoncini E, Pagani O, Price K, Aebi S, Mendiola C, Thürlimann B, Colleoni M, Collins J, Crivellari D, Lindtner J, Rotmensz N, Dellapasqua S, Goldhirsch A. CA15-3 and alkaline phosphatase as predictors for breast cancer recurrence: a combined analysis of seven International Breast Cancer Study Group trials. *Ann Oncol* 2007; 18:701-8.

Colleoni M, Veronesi A, Holmberg S, Erzen D, Forbes J, Murray E, Thürlimann B, Simoncini E, Pagani O, Collins J, Crivellari D, Rudenstam C, Lindtner J, Price K, Castiglione-Gertsch M, Coates A, Gelber R, Li S, Goldhirsch A. Timing of CMF chemotherapy in combination with tamoxifen in postmenopausal women with breast cancer: role of endocrine responsiveness of the tumor. *Ann Oncol* 2005; 16:716-25.

Colleoni M, Collins J, Thürlimann B, Holmberg S, Crivellari D, Beyerle C, Neumann R, Goldhirsch A, International Breast Cancer Study Group, Lindtner J, Schmoor C, Rudenstam C, Litman H, Castiglione-Gertsch M, Sauerbrei W, Gelber R, Bonetti M, Coates A, Schumacher M, Bastert G, German Breast Cancer Study Group. Duration of adjuvant chemotherapy for breast cancer: a joint analysis of two randomised trials investigating three versus six courses of CMF. *British journal of cancer* 2002; 86:1705-14.

Colleoni M, Goldhirsch A, Fey M, Murray E, Simoncini E, Cortes-Funes H, Holmberg S, Thürlimann B, Collins J, Lindtner J, Rudenstam C, Price K, Gelber R, Castiglione-Gertsch M, Coates A, Gelber S, International Breast Cancer Study Group. Influence of endocrine-related factors on response to perioperative chemotherapy for patients with node-negative breast cancer. *Journal of clinical oncology : official journal of the American Society of Clinical Oncology* 2001; 19:4141-9.

Colleoni M, Senn H, Cavalli F, Forbes J, Gudgeon A, Simoncini E, Cortes-Funes H, Veronesi A, Fey M, Collins J, Lindtner J, O'Neill A, Goldhirsch A, Gelber R, Bonetti M, Thürlimann B, Price K, Castiglione-Gertsch M, Coates A, Rudenstam C. Identifying breast cancer patients at high risk for bone metastases. *Journal of clinical oncology : official journal of the American Society of Clinical Oncology* 2000; 18:3925-35.

Colleoni M, Marini G, Veronesi A, Holmberg S, Thürlimann B, Collins J, Lindtner J, Rudenstam C, Price K, Gelber R, Castiglione-Gertsch M, Coates A, Bonetti M, Goldhirsch A. Early start of adjuvant chemotherapy may improve treatment outcome for premenopausal breast cancer patients with tumors not expressing estrogen receptors. The International Breast Cancer Study Group. *Journal of clinical oncology : official journal of the American Society of Clinical Oncology* 2000; 18:584-90.

Colleoni M, Thürlimann B, Gelber R, Collins J, Lindtner J, Coates A, Goldhirsch A, Castiglione-Gertsch M, Price K, Rudenstam C. Dose-response effect of adjuvant cyclophosphamide, methotrexate, 5-fluorouracil (CMF) in node-positive breast cancer. International Breast Cancer Study Group. *European journal of cancer (Oxford, England : 1990)* 1998; 34:1693-700.

Projects (0)

No results found.

Kantonsspital St.Gallen

Rorschacher Strasse 95

CH-9007 St.Gallen

T: +41 71 494 11 11

support.forschung@kssg.ch